<DOC>
	<DOCNO>NCT00308269</DOCNO>
	<brief_summary>This Phase I clinical trial evaluate safety tolerability escalate dos vintafolide ( EC145 ) participant relapse refractory advanced tumor . The primary objective study determine safety maximum tolerate dose vintafolide give intravenous bolus infusion . The efficacy treatment also measure .</brief_summary>
	<brief_title>Study Vintafolide ( MK-8109 , EC145 ) Treatment Recurrent Refractory Solid Tumors ( MK-8109-006 , EC-FV-01 )</brief_title>
	<detailed_description>This dose escalation study vintafolide administer intravenous ( IV ) bolus infusion week 1 3 4-week cycle participant solid tumor refractory current therapy . Vintafolide drug specifically design enter cell via folate vitamin receptor . Experimental evidence show target receptor over-expressed many human cancer . There previous human study vintafolide treatment ; however , lab research ( research test tube and/or animal ) use vintafolide show activity tumor animal . This activity animal model suggest vintafolide may useful chemotherapy human cancer .</detailed_description>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vinca Alkaloids</mesh_term>
	<criteria>Histological cytological diagnosis neoplasm No effective standard therapeutic option Eastern Cooperative Oncology Group ( ECOG ) performance status 02 &gt; =4 week post therapeutic radiation chemotherapy &gt; =6 week nitrosoureas mitomycin C ) recovery associate toxicity Negative serum pregnancy test woman childbearing potential willingness practice contraceptive method Adequate bone marrow reserve , renal , hepatic function Concurrent hematological malignancy Women pregnant lactate Evidence symptomatic brain metastasis Receiving concomitant anticancer therapy ( exclude supportive care ) Requires palliative radiotherapy time study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Phase I</keyword>
	<keyword>EC145</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Refractory</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Experimental</keyword>
</DOC>